Physician profile
Luis A Murrain
NPI 1285749788
$612.79
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.76 · 2020: $153 · 2021: $211 · 2022: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $277.67 | 2020-2022 | |
| Novo Nordisk INC | $130.66 | 2019-2022 | |
| Lilly USA, LLC | $51.99 | 2019-2021 | |
| Astellas Pharma US INC | $40.95 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $28.88 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $24.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.63 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.53 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.46 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Murrain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.